Auranofin is an effective agent against clinical isolates of Staphylococcus aureus

Nagendran Tharmalingam, Noelly Q. Ribeiro, Danielle L. Da Silva, Mandar T. Naik, Lana I.B. Cruz, Wooseong Kim, Steven Shen, Jéssica D. Dos Santos, Katarina Ezikovich, Erika M.C. D'Agata, Eleftherios Mylonakis, Beth B. Fuchs

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.

Original languageEnglish
Pages (from-to)1417-1425
Number of pages9
JournalFuture Medicinal Chemistry
Volume11
Issue number12
DOIs
StatePublished - 2019

Bibliographical note

Funding Information:
Funding was made available to EMCD through an award from the National Institute of Allergy and Infectious Diseases (K24 AI119158). The research was also funded through an National Institute of Health grant (P20GM121344). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Funding Information:
Made available to EMCD through an award from the National Institute of Allergy and Infectious Diseases (K24 AI119158). The research was also funded through an National Institute of Health grant (P20GM121344). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Publisher Copyright:
© 2019 Newlands Press.

Keywords

  • MRSA
  • Staphylococcus aureus
  • VISA
  • antimicrobial
  • auranofin
  • drug-resistant bacteria
  • thioredoxin reductase

Fingerprint

Dive into the research topics of 'Auranofin is an effective agent against clinical isolates of Staphylococcus aureus'. Together they form a unique fingerprint.

Cite this